Stock SCD ZENTIVA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zentiva S.A.

Equities

SCD

ROSCDBACNOR8

Pharmaceuticals

End-of-day quote Bucharest S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
3.38 RON +1.20% Intraday chart for Zentiva S.A. +6.29% +15.75%
Apr. 01 Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution CI
Feb. 29 Zentiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,543 2,230 2,021 1,701 1,352 2,035
Enterprise Value (EV) 1 1,138 1,856 1,620 1,647 1,360 2,029
P/E ratio 5.87 x 39.1 x 30.8 x 16.1 x 13.6 x 10.6 x
Yield - - - - - -
Capitalization / Revenue 3.34 x 3.99 x 3.62 x 2.49 x 1.78 x 2.13 x
EV / Revenue 2.47 x 3.32 x 2.9 x 2.41 x 1.79 x 2.13 x
EV / EBITDA 3.53 x 29.4 x 18.7 x 12.6 x 12.2 x 9.73 x
EV / FCF 5.1 x -25.5 x 1,151 x -4.51 x -15 x -43.6 x
FCF Yield 19.6% -3.92% 0.09% -22.2% -6.68% -2.3%
Price to Book 2.45 x 3.18 x 2.57 x 1.91 x 1.35 x 1.71 x
Nbr of stocks (in thousands) 416,961 697,017 697,017 697,017 697,017 697,017
Reference price 2 3.700 3.200 2.900 2.440 1.940 2.920
Announcement Date 4/1/19 3/27/20 4/29/21 5/3/22 3/28/23 3/27/24
1RON in Million2RON
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 461.4 559 558 683.9 759.6 953.6
EBITDA 1 322.4 63.2 86.45 130.7 111.3 208.5
EBIT 1 310.3 46.68 67.52 107.3 85.71 185.4
Operating Margin 67.25% 8.35% 12.1% 15.69% 11.28% 19.44%
Earnings before Tax (EBT) 1 315.4 54.09 80.55 119.2 115 221.8
Net income 1 262.6 43.75 65.64 105.7 99.47 192.6
Net margin 56.92% 7.83% 11.76% 15.46% 13.09% 20.2%
EPS 2 0.6298 0.0819 0.0942 0.1517 0.1427 0.2763
Free Cash Flow 1 223.2 -72.75 1.407 -365.2 -90.89 -46.57
FCF margin 48.37% -13.01% 0.25% -53.41% -11.96% -4.88%
FCF Conversion (EBITDA) 69.22% - 1.63% - - -
FCF Conversion (Net income) 84.98% - 2.14% - - -
Dividend per Share - - - - - -
Announcement Date 4/1/19 3/27/20 4/29/21 5/3/22 3/28/23 3/27/24
1RON in Million2RON
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 7.62 -
Net Cash position 1 405 375 401 53.2 - 6.15
Leverage (Debt/EBITDA) - - - - 0.0685 x -
Free Cash Flow 1 223 -72.8 1.41 -365 -90.9 -46.6
ROE (net income / shareholders' equity) 52.6% 6.57% 8.83% 12.6% 10.5% 17.6%
ROA (Net income/ Total Assets) 27.8% 3.05% 4.11% 6.44% 4.75% 8.57%
Assets 1 944.8 1,437 1,595 1,642 2,093 2,248
Book Value Per Share 2 1.510 1.010 1.130 1.280 1.430 1.710
Cash Flow per Share 2 0.9700 0.5600 0.5800 0.0900 0.0200 0.0400
Capex 1 22.2 35.6 24.5 22.9 27.4 28
Capex / Sales 4.82% 6.36% 4.4% 3.35% 3.61% 2.93%
Announcement Date 4/1/19 3/27/20 4/29/21 5/3/22 3/28/23 3/27/24
1RON in Million2RON
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
ZENTIVA S.A. Stock Zentiva S.A.
+15.75% 505M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SCD Stock
  4. Financials Zentiva S.A.